Skip to main content

Table 3 Model 2. Relation of lnFGF23 in the full adjusted model with cardiovascular and renal risk factors

From: Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

Variable

B

Standard error

Beta

p-value

eGFR (MDRD, ml/min/1.73 m 2 )

-0.022

0.003

-034

< 0.001

Phosphate (mmol/l)

0.297

0.131

0.082

0.024

lnPTH (pmol/l)

0.244

0.047

0.196

< 0.001

Calcium (mmol/l)

0.393

0.220

0.062

0.075

Proteinuria (gram/24 hours)

0.064

0.021

0.113

0.002

Male

-0.094

0.071

-0.048

0.183

Smoking

0.313

0.073

0.148

< 0.001

BMI

0.003

0.007

0.017

0.638

Diabetes Mellitus

0.159

0.075

0.075

0.035

History CVD

0.224

0.071

0.113

0.002

Age (year)

0.001

0.003

0.006

0.868

Systolic blood pressure (mmHg)

-0.001

0.002

-0.02

0.586

Total cholesterol (mmol/l)

0.006

0.031

0.007

0.848

Active vitamin D use

0.096

0.079

0.044

0.223

  1. Model 2: multivariable analyses of relation of lnFGF23 with Framingham risk factors (model 1) and renal risk factors. B reflects change in lnFGF23 per unit change in the variable. For dichotomous variables (sex, smoking, diabetes, and history of CVD) B reflects lnFGF23 change in the presence of the depicted variable. Beta is the standardized B to compare influence on lnFGF23 between variables.
  2. eGFR: estimated glomerular filtration rate; MDRD: four-point MDRD-formula; BMI: Body mass index; CVD: cardiovascular disease